News
Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker ...
Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...
Rivus Pharmaceuticals’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the ...
A research team was looking to make a new anti-inflammatory medication when they found some incredible side effects ...
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm.
Drugmakers are racing to develop the next wave of obesity and diabetes medications that they hope will be even more powerful ...
A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback